Executive Chairman and Co-Founder, Allogene Therapeutics Inc.
THE LATEST: Belldegrun took his gene therapy cancer treatment company from a 2017 launch to a September 2018 initial public offering, raising $324 million. The Southern California-based executive this year announced plans for a 118,000-square-foot cell therapy manufacturing facility in Newark for Allogene, which is based in South San Francisco.
BACKGROUND: Belldegrun previously founded cancer biopharmaceutical company Kite Pharma, which was acquired by Gilead Sciences Inc. in 2017 for about $12 billion. Belldegrun has founded or helped build a number of biopharma companies, including Cougar Biotechnology Inc. and Agensys Inc. He also is chairman of the Two River Group Holdings, UroGen Pharma Ltd. and Kronos Bio Inc., and serves as a senior managing director of Vida Ventures, a life-sciences investment firm he co-founded.
WORTH NOTING: Belldegrun is a physician who earned his medical degree from Hebrew University Hadassah Medical School in Jerusalem. He remains a professor of urology and is a director of the UCLA Institute of Urology.
YEARS ON THE LA500: 4
For reprint and licensing requests for this article, CLICK HERE.
Stories You May Also Be Interested In
- Arie Belldegrun, MD
- Kite Pharma Vets Link to Pfizer
- Former Kite Execs Team With Pfizer to Create Biotech Co. to Treat Cancer
- Biotech Band Back Together
- Professor as Entrepreneur: UCLA’s Belldegrun on to Next Biopharma Enterprise
- Kite Adds Production in Europe
- LA 500: Arie Belldegrun
- Allogene Therapeutics Raises $324 Million in IPO as Shares Soar